BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15380214)

  • 1. Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivatives.
    Watkins WJ; Lemoine RC; Chong L; Cho A; Renau TE; Kuo B; Wong V; Ludwikow M; Garizi N; Iqbal N; Barnard J; Jankowska R; Singh R; Madsen D; Lolans K; Lomovskaya O; Oza U; Dudley MN
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5133-7. PubMed ID: 15380214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinazolinone-based fungal efflux pump inhibitors. Part 1: Discovery of an (N-methylpiperazine)-containing derivative with activity in clinically relevant Candida spp.
    Lemoine RC; Glinka TW; Watkins WJ; Cho A; Yang J; Iqbal N; Singh R; Madsen D; Lolans K; Lomovskaya O; Oza U; Dudley MN
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5127-31. PubMed ID: 15380213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimization.
    Watkins WJ; Chong L; Cho A; Hilgenkamp R; Ludwikow M; Garizi N; Iqbal N; Barnard J; Singh R; Madsen D; Lolans K; Lomovskaya O; Oza U; Kumaraswamy P; Blecken A; Bai S; Loury DJ; Griffith DC; Dudley MN
    Bioorg Med Chem Lett; 2007 May; 17(10):2802-6. PubMed ID: 17350259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry.
    Pina-Vaz C; Rodrigues AG; Costa-de-Oliveira S; Ricardo E; Mårdh PA
    J Antimicrob Chemother; 2005 Oct; 56(4):678-85. PubMed ID: 16115827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel hybrids of fluconazole and furanones: design, synthesis and antifungal activity.
    Borate HB; Sawargave SP; Chavan SP; Chandavarkar MA; Iyer R; Tawte A; Rao D; Deore JV; Kudale AS; Mahajan PS; Kangire GS
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4873-8. PubMed ID: 21757344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.
    Holmes AR; Keniya MV; Ivnitski-Steele I; Monk BC; Lamping E; Sklar LA; Cannon RD
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1508-15. PubMed ID: 22203607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The comparison of susceptibility of Candida albicans and Candida glabrata to miconazole].
    Kurnatowski P; Makieło L; Horwatt-Bozyczko E
    Wiad Parazytol; 2001; 47(4):867-73. PubMed ID: 16886440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes.
    Ricardo E; Costa-de-Oliveira S; Dias AS; Guerra J; Rodrigues AG; Pina-Vaz C
    FEMS Yeast Res; 2009 Jun; 9(4):618-25. PubMed ID: 19416368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.
    Mai A; Rotili D; Massa S; Brosch G; Simonetti G; Passariello C; Palamara AT
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1221-5. PubMed ID: 17196388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated lactoferrin and fluconazole synergism against Candida albicans and Candida glabrata vaginal isolates.
    Naidu AS; Fowler RS; Martinez C; Chen J; Tulpinski J
    J Reprod Med; 2004 Oct; 49(10):800-7. PubMed ID: 15568403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.
    Quan H; Cao YY; Xu Z; Zhao JX; Gao PH; Qin XF; Jiang YY
    Antimicrob Agents Chemother; 2006 Mar; 50(3):1096-9. PubMed ID: 16495278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum repressing efflux pump CDR1 in Candida albicans.
    Yang YL; Lin YH; Tsao MY; Chen CG; Shih HI; Fan JC; Wang JS; Lo HJ
    BMC Mol Biol; 2006 Jul; 7():22. PubMed ID: 16839415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
    De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
    J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antimicrobial activity of some 1,5-diaryl-2-methyl-3- carbethoxy-4-(4-methyl-piperazin-1-ylmethyl)-pyrroles and some 1,5-diaryl-2- methyl-3,4-di(4-methyl-piperazin-1-ylmethyl)-pyrroles.
    Cerreto F; Scalzo M; Villa A
    Farmaco; 1993 Dec; 48(12):1735-46. PubMed ID: 8135996
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.
    Pancholi P; Park S; Perlin D; Kubin C; Della-Latta P
    J Clin Microbiol; 2004 Dec; 42(12):5938-9. PubMed ID: 15583347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
    Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
    J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance.
    Niimi M; Niimi K; Takano Y; Holmes AR; Fischer FJ; Uehara Y; Cannon RD
    J Antimicrob Chemother; 2004 Dec; 54(6):999-1006. PubMed ID: 15486081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid core nanoparticles as a broad strategy to reverse fluconazole resistance in multiple Candida species.
    Domingues Bianchin M; Borowicz SM; da Rosa Monte Machado G; Pippi B; Stanisçuaski Guterres S; Raffin Pohlmann A; Meneghello Fuentefria A; Clemes Külkamp-Guerreiro I
    Colloids Surf B Biointerfaces; 2019 Mar; 175():523-529. PubMed ID: 30579053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety.
    Lebouvier N; Pagniez F; Duflos M; Le Pape P; Na YM; Le Baut G; Le Borgne M
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3686-9. PubMed ID: 17482460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.